Natalizumab and Beyond

Yıldız, Murat; Tettenborn, Barbara; Putzki, Norman

doi:10.1159/000317583

Cited by 3 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In patients with MS living in temperate and Nordic countries, as in the general populations of these countries, vitamin D insufficiency is widespread, whatever the cutoff (50 or 75 nmol/ liter) for the lower limit of the 25-OH-D serum level ( Figure 3): indeed, as early as the earliest stages of the disease, that is, in patients with clinically isolated syndrome (CIS) or with RRMS, average serum levels are between 42 and 74 nmol/ liter, depending on the studies and the seasons, with a general mean close to 60 nmol/liter [SoiluHänninen et al 2005[SoiluHänninen et al , 2012Smolders et al 2008b;Hiremath et al 2009;Kragt et al 2009;Mowry et al 2010;Pierrot-Deseilligny andSouberbielle, 2010, 2012;Simpson et al 2010;Banwell et al 2011;Dabbaghmanesh and Yousefipour, 2011;Lonergan et al 2011;Neau et al 2011;Steffensen et al 2011;Yildiz et al 2011; Bäärnhielm Kampman et al 2012;Kirbas et al 2012;Løken-Amsrud et al 2012;Moen et al 2012;Runia et al 2012;SoiluHänninen et al 2012;Šaltyte . Benth et al 2012;Triantafyllou et al 2012] (Table 1).…”

Section: Vitamin D Requirements and Insufficiencymentioning

confidence: 99%

See 1 more Smart Citation

Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis

Pierrot‐Deseilligny

Souberbielle

2013

Ther Adv Neurol Disord

View full text Add to dashboard Cite

Abstract:The contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis (MS) is reviewed. Among the multiple recently discovered actions of vitamin D, an immunomodulatory role has been documented in experimental autoimmune encephalomyelitis and in humans. This action in the peripheral immune system is currently the main known mechanism through which vitamin D might influence MS, but other types of actions could be involved within the central nervous system. Furthermore, vitamin D insufficiency is widespread in temperate countries and in patients with MS at the earliest stages of the disease, suggesting that the deleterious effects related to vitamin D insufficiency may be exerted in these patients. In fact, many genetic and environmental risk factors appear to interact and contribute to MS. In genetics, several human leukocyte antigen (HLA) alleles (more particularly HLA-DRB1*1501) could favour the disease whereas some others could be protective. Some of the genes involved in vitamin D metabolism (e.g. CYP27B1) also play a significant role. Furthermore, three environmental risk factors have been identified: past Epstein-Barr virus infection, vitamin D insufficiency and cigarette smoking. Interactions between genetic and environmental risk or protective factors may occur during the mother's pregnancy and could continue during childhood and adolescence and until the disease is triggered in adulthood, therefore possibly modulating the MS risk throughout the first decades of life. Furthermore, some clinical findings already strongly suggest that vitamin D status influences the relapse rate and radiological lesions in patients with MS, although the results of adequately powered randomized clinical trials using vitamin D supplementation have not yet been reported. While awaiting these incontrovertible results, which might be long in coming, patients with MS who are currently in vitamin D insufficiency should be supplemented, at least for their general health status, using moderate doses of the vitamin.

show abstract

Section: Vitamin D Requirements and Insufficiencymentioning

confidence: 99%

“…; Pierrot-Deseilligny andSouberbielle, , 2012Simpson et al 2010;Banwell et al 2011;Dabbaghmanesh and Yousefipour, 2011;Lonergan et al 2011;Neau et al 2011;Steffensen et al 2011;Yildiz et al 2011; …”

unclassified

Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis

Pierrot‐Deseilligny

Souberbielle

2013

Ther Adv Neurol Disord

View full text Add to dashboard Cite

show abstract

“…Natalizumab blocks integrin association with vascular receptors in many tissues besides the gut-specific alpha 4 beta 7 , limiting trafficking out of the bloodstream so much so that natalizumab-treated patients can show a peripheral lymphocytosis (108,109). While approved for use in Crohn's disease and multiple sclerosis, safety issues related to the susceptibility to developing progressive multifocal leukoencephelopathy mandates that current use of natalizumab be discontinued in Crohn's disease if no therapeutic benefit is observed in the first 12 weeks of therapy (109)(110)(111). The investigational drug vedolizumab (MLN-0002/LDP-02) is a humanized monoclonal antibody also directed against an adhesion molecule.…”

Section: Inhibition Of Cell Traffickingmentioning

confidence: 99%

Inflammatory bowel diseases emerging therapies and promising molecular targets

Malik

Mannon

2012

Front Biosci

View full text Add to dashboard Cite

An enormous amount of pathoetiologic information continues to accrue from animal models of inflammatory bowel disease and study of the gut microbiome that is providing expanded insight into the causes and mechanisms of inflammatory bowel diseases. This knowledge is being translated into new therapeutics that are being tested in Crohn's and ulcerative colitis patients with an aim to enhance treatment responses by moving away from immunosuppression and toward immunomodulation. In the last decade, the frontier of emerging IBD therapy has been dominated by biological agents that specifically target pro-inflammatory cytokines most notably tumor necrosis factor-alpha. However, it is clear that the gaps in therapy (primary and secondary non-response and the potential for drug side effects and intolerances) continue. To fill these gaps, various approaches are being employed to develop novel strategies, from inhibiting additional pro-inflammatory cytokines to focusing on blocking inflammatory cell trafficking, decreasing inflammatory cell mass, enhancing regulatory cell function and reinforcing epithelial barrier function. To these ends, aggressive and innovative research is being pursued to develop more robust treatment strategies and identify key molecular targets.

show abstract

Advances in Management of Crohn’s Disease

Malik¹

2012

Crohn's Disease

View full text Add to dashboard Cite

show abstract

Natalizumab and Beyond

Cited by 3 publications

References 31 publications

Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis

Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis

Inflammatory bowel diseases emerging therapies and promising molecular targets

Advances in Management of Crohn’s Disease

Contact Info

Product

Resources

About